Błażej B.’s Post

Fujitsu and Riken Research Institute join forces to accelerate drug discovery with generative AI technology, predicting protein structures over 10 times faster than current methods. The breakthrough, leveraging advanced cryo-electron microscopy, enables the reproduction of proteins in 3D motion, expediting the estimation of drug-target protein shapes and movements. Trials are slated for fiscal 2024, with Fujitsu engaging pharmaceutical companies and universities through the Life Intelligence Consortium. Expected outcomes include faster drug development, focused resources on promising candidates, and potential treatments for infectious diseases. #Fujitsu #Riken #AI #DrugDiscovery #GenerativeAI #MedicalResearch

AI in Drug Discovery Market to Grow $4.9 Billion by 2028 Download Sample PDF Report-https://lnkd.in/d_AmJM2t The size of global AI in the drug discovery market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 40.2% from 2023 to 2028. Companies Working in the Market NVIDIA Exscientia Google BenevolentAI Recursion Insilico Medicine Schrödinger Microsoft Atomwise Illumina NuMedii XtalPi Inc. iktos Arterys (Acquired by Tempus Labs) Deep Genomics Verge Genomics BenchSci insitro Valo Health BPGbio, Inc. Predictive Oncology Labcorp IQVIA IGE/Affinity Media (acq. Tencent Holdings Ltd.) Celsius Therapeutics CytoReason Owkin Cloud Pharmaceuticals, Inc. Evaxion Biotech A/S Standigm BioAge Labs Envisagenics ARIAD Pharmaceuticals, Inc.

Bioinformatics is revolutionizing the pharmaceutical field by: Accelerating Drug Discovery: Using computational tools to identify drug targets and screen compounds. Enabling Personalized Medicine: Analyzing genetic data to tailor treatments for individuals. Enhancing Clinical Trials: Designing and analyzing trials for better patient outcomes. Discovering Biomarkers: Identifying markers for disease diagnosis and treatment monitoring.

Last year ended on news of some major AI - Pharma collaborations, and 2024 is starting strong on this front too, with 2 major deals announced with Alphabet Isomorphic partnering with both Eli Lilly and Novartis. Alphabets AI platform is able to predict protein structure and so could potentially speed up target discovery and compound construction. These deals are worth almost $ 3 billion combined, showing huge confidence in the positive effect AI could have on drug discovery. https://lnkd.in/eesvnfAu

I’m pleased to announce that I’ll be presenting at BIOVIA Live! 🎤 Join me as I explore the groundbreaking deep learning and AI-based tools within Discovery Studio that are revolutionizing biologics research. In my talk, I’ll highlight: 🔹 OpenFold and AlphaFold Multimer for precise protein structure prediction 🔹 RFDiffusion for designing innovative protein scaffolds 🔹 Protein MPNN for efficient sequence optimization Additionally, I’ll showcase how our AI-enhanced solutions for antibody humanization are streamlining therapeutic design, and the deep learning-driven paratope prediction that provides unparalleled accuracy in epitope identification. These advancements are empowering researchers with unprecedented capabilities to accelerate and refine the biologics development process. I can’t wait to share insights and explore the future of biologics research together! See you there! 🚀 #BIOVIALive #Biologics #AI #DeepLearning #ResearchInnovation

VantAI’s geometric deep learning capabilities meet BMS’s targeted protein degradation expertise to discover and develop new small molecule therapeutics. • Focus on identifying molecular glues against targets of interest with an option to expand to additional programs • VantAI is eligible to receive up to $674 million in discovery, development, clinical, regulatory, and sales milestone payments plus tiered royalties from BMS #generativeai #artificialintelligence #biotech #pharma #collaboration #scienceandtechnology #stem #science #technology #engineering #mathematics #deeplearning #ml #innovation #geometric #geometricdeeplearning #drugdiscovery #ai

Recently I read an article published on BioPharm International, Volume 35, Number 11, November 2022, Pages: 10-15 by Cynthia A. Challener, PhD. I would like to put my thoughts into a discussion with like-minded people. 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: 𝐍𝐞𝐰 𝐌𝐨𝐝𝐚𝐥𝐢𝐭𝐢𝐞𝐬, 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞, 𝐚𝐧𝐝 𝐀𝐈 𝐢𝐧 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 As highlighted in the recent article by the Author, the increasing molecular diversity of new drug modalities such as 𝐦𝐑𝐍𝐀, 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 is driving a need for innovation in 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. The complexity of these therapies, from process automation challenges to raw material supply chain constraints, presents exciting opportunities for innovation. With 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 becoming a key focus, it’s clear that new technologies, including 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐦𝐨𝐝𝐞𝐥𝐥𝐢𝐧𝐠 𝐚𝐧𝐝 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧, are critical to improving the efficiency of biologics development. How can we ensure that AI tools, 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 (𝐏𝐀𝐓), and digital simulations evolve to keep pace with the rapid development of these new modalities? I'd love to hear your thoughts on: 1. How AI can streamline 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬. 2. The role of 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 in shaping future development. 3. Ways to tackle supply chain and process complexity for 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. Let's discuss how we can continue to innovate in biologics to deliver safe, effective therapies to patients faster. #Biologics #NewModalities #AIinHealthcare #PersonalisedMedicine #ProcessDevelopment #BiotechInnovation #Pharma

Transform Your Drug Discovery Process with Wisecube’s #Orpheus! 💊 🔬 Are you ready to revolutionize your approach to drug discovery? Learn how Wisecube's Orpheus is redefining the research with groundbreaking #AI technology. 🧬 Orpheus, a cutting-edge 3D convolutional neural network, leverages a vast biomedical knowledge graph to predict molecular fingerprints, suggest alternative compounds, and enhance lead optimization with unparalleled accuracy. 💡 Experience the future of drug development: rapid compound identification, AI-powered predictions of bioactivity, and comprehensive ADMET property analysis. 🌟 Join leading organizations like the #IDRI (Infectious Disease Research Institute), who have already harnessed Orpheus to overcome challenges and accelerate their drug discovery process. 📊 Dive into our latest success stories and understand how Orpheus can transform your research endeavors. 👉 Don't miss this opportunity to be at the forefront of therapeutic innovation. Visit our website to learn more, and schedule a demo today to see Orpheus in action!  Discover Orpheus Now >> https://lnkd.in/eriXwQzZ #DrugDiscovery #DrugDevelopment #DrugDesign #AIDrivenResearch #BiomedicalResearch #GraphAI #Biomedical #Biopharma #Biotech #Biomedicine 

Google DeepMind's new AlphaFold can model a much larger slice of biological life, offering significant advancements in understanding and predicting the structure of various biological molecules. This can accelerate drug discovery, enhance precision medicine, and transform pharmaceutical research. #GoogleDeepMind #Google #Healthcare #PharmaceuticalResearch #DrugDiscovery #PrecisionMedicine Google Deepmind's new AlphaFold can model a much larger slice of biological life